Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)

Brendan J. Guercio(University of Rochester), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Himisha Beltran(Dana-Farber Cancer Institute), Ronak Shah(Memorial Sloan Kettering Cancer Center), Susan Halabi(Duke Medical Center), Jennifer H. Milbank(Memorial Sloan Kettering Cancer Center), Ashley Marie Regazzi(Memorial Sloan Kettering Cancer Center), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Gopa Iyer(Memorial Sloan Kettering Cancer Center), Karla V. Ballman(Mayo Clinic in Arizona), Michael J. Morris(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Karissa Whiting(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Venkatraman Seshan(Memorial Sloan Kettering Cancer Center)
European Urology Open Science
April 8, 2025
10.1016/j.euros.2025.03.009
Cited by 3

Related Papers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k